Actavis' Namenda switch exceeds expectations, and its ability to supply new version

Usually, exceeding expectations when it comes to a sales goal is a good thing. But in the case of Actavis ($ACT) and its forced switch of patients to a once-daily version of its Alzheimer's treatment Namenda, it is posing some problems--supply problems. The company announced earlier that it would stop production in August of the original version, a move that would leave patients no choice but to switch to the patent protected extended release product, and so keep most of the sales. It has since said it will continue to make it into the fall and conceded to Bloomberg that it is having trouble keeping up with demand for the new capsule. Story | More

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.